KRAS and non-small cell lung carcinoma: We treated A549 and HCC827 cells, two NSCLC cell lines harboring aberrant MAPK signaling (KRAS-G12S and EGFR mutation, respectively), with two ERK inhibitors, BVD-523 (BVD) and SCH772984 (SCH), at a dose (2.5 μM) that is around their IC50 (Figure S2A-B).